Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmplia Therapeutics Ltd

Amplia Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.089 AUD -0.00 ( 1.11%)
Last update at 2026-11-06T05:10:00Z
VOLUME
706919
Market Cap
44.14M

Momentum Score

…

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.09
Low
0.09
High
52 Week Price Range
0.08
Low
0.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amplia Therapeutics Ltd is an Australian clinical-stage biotechnology company listed on the ASX with limited publicly available program detail. Long-term growth drivers include clinical development progress, regulatory approvals, and partnerships or licensing that could convert R&D into revenue. Investors may find the company attractive for liquid exposure to potential high-reward clinical milestones if programs advance and capital requirements are managed.
The principal risks include clinical or regulatory failure, the frequent need for additional financing with dilution risk, and a limited commercial track record common to small biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.09
Dividend Yield
-
Revenue TTM
4.79M
Revenue Per Share
0.01
Gross Profit TTM
4.41M
Debt / Equity
0.01
ROE
-25.48%
Net Debt
-27.51M
ROCE
-33.14%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -12.49M -6.57M -8.94M -6.24M -3.64M
Net income -7.71M -6.57M -4.50M -6.30M -3.65M
Selling general administrative - 2.67M 2.60M 2.41M 1.70M
Selling and marketing expenses - 0.08M 0.09M - -
Gross profit -0.09M 3.57M 4.01M - -
Reconciled depreciation - 0.09M 0.09M 0.07M 0.00M
Ebit -13.18M -6.79M -4.57M -6.19M -3.64M
Ebitda -13.09M -6.78M -4.48M -6.12M -3.64M
Depreciation and amortization 0.09M 0.01M 0.09M 0.07M 0.00M
Operating income -13.18M -6.52M -4.42M -6.19M -3.64M
Other operating expenses 13.18M 10.30M 8.88M 7.48M 5.63M
Interest expense 0.02M 0.06M 0.08M 0.05M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.22M 0.15M 0.10M 0.00M
Net interest income - 0.22M 0.07M 0.04M -0.00M
Income tax expense -4.78M -3.77M -4.44M 0.05M 0.00M
Total revenue - 3.78M 4.45M 1.15M 1.98M
Total operating expenses 13.09M 10.09M 8.44M 7.48M 5.63M
Cost of revenue 0.09M 0.21M 0.44M - -
Total other income expense net 0.69M -0.06M -4.52M -0.05M -0.00M
Net income from continuing ops - -6.57M -4.50M -6.24M -3.64M
Net income applicable to common shares - -6.57M -4.50M -6.24M -3.64M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 41.44M 22.94M 14.85M 18.68M 24.48M
Intangible assets 7.94M 7.94M - 7.94M 7.94M
Other current assets 0.41M 0.18M 0.19M 0.07M 0.05M
Total liab 1.97M 1.91M 3.43M 2.85M 2.64M
Total stockholder equity 39.47M 21.02M 11.42M 15.84M 21.85M
Other current liab 0.18M - 0.25M 2.40M 0.16M
Common stock 193.43M - 151.53M 151.53M 151.51M
Capital stock - 167.39M - 151.53M 151.51M
Retained earnings -152.83M -145.54M -139.01M -134.72M -128.62M
Other liab - - - 0.00M 0.01M
Other assets - - - 0.05M -
Cash 27.85M 10.86M 3.39M 9.26M 14.61M
Cash and equivalents - - - 7.98M 10.62M
Total current liabilities 1.67M 1.89M 3.40M 2.75M 0.53M
Current deferred revenue - - - -2.18M -2.18M
Net debt -27.51M - -1.82M -6.98M -12.51M
Short term debt 0.09M - 1.55M 2.18M 2.18M
Short long term debt - - - 2.11M -
Short long term debt total 0.34M - 1.56M 2.28M 2.10M
Other stockholder equity - - - -0.97M -1.04M
Property plant equipment - - - 0.18M 0.01M
Total current assets 33.04M 14.93M 6.75M 10.51M 16.53M
Net tangible assets - - - 7.90M 13.91M
Net receivables 4.78M - 3.18M 1.15M 1.84M
Long term debt - - - 0.00M 2.10M
Inventory - - - 0.04M 0.03M
Accounts payable 1.40M 1.56M 1.60M 0.35M 0.37M
Accumulated other comprehensive income -1.13M - -1.10M -0.97M -1.04M
Non currrent assets other 0.11M 0.05M 7.99M 0.05M -7.95M
Non current assets total 8.40M 8.01M 8.09M 8.18M 7.95M
Capital lease obligations - 0.01M - 0.17M -
Long term debt total - - - 0.09M 2.10M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -0.00M -0.00M -0.06M -0.01M
Change to liabilities - - - -0.01M 0.00M
Total cashflows from investing activities -0.10M -0.00M -0.00M -0.06M -0.03M
Net borrowings - - -0.63M -0.06M 2.10M
Total cash from financing activities 25.94M 14.32M -0.77M -0.08M 17.19M
Net income -7.71M -6.57M -4.50M -6.24M -3.64M
Change in cash 16.99M 7.48M -5.87M -5.35M 12.76M
Begin period cash flow 10.86M 3.39M 9.26M 14.61M 1.85M
End period cash flow 27.85M 10.86M 3.39M 9.26M 14.61M
Total cash from operating activities -8.73M -6.89M -5.13M -5.29M -4.40M
Issuance of capital stock - 17.28M 0.00M 0.02M 16.27M
Depreciation 0.09M - 0.09M 0.07M 0.00M
Other cashflows from investing activities -0.06M - 0.00M -0.04M -0.01M
Change to account receivables -1.10M -0.67M -2.04M 0.68M -0.83M
Sale purchase of stock - -1.33M 0.00M 0.02M -1.18M
Other cashflows from financing activities -0.09M -0.16M -0.14M -0.04M 2.10M
Change to netincome - - - 0.21M 0.06M
Capital expenditures 0.03M 0.00M 0.00M 0.02M 0.01M
Change in working capital -1.39M -0.53M -0.80M 0.68M -0.83M
Stock based compensation - - 0.09M 0.21M 0.06M
Other non cash items 0.27M -6.35M 0.09M 0.88M -0.76M
Free cash flow -8.77M -6.89M -5.13M -5.31M -4.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ATX
Amplia Therapeutics Ltd		 -0.00
1.11%		 0.09 - - 9.21 1.09 759.37 -1.65
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Amplia Therapeutics Ltd

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

90 William Street, Melbourne, VIC, Australia, 3000

61 3 9123 1140

https://www.ampliatx.com

Name Title Year Born
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director 1964
Mr. Hamish George Chief Financial Officer NA
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer NA
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology NA
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec. 1960
Dr. Frank Gelder Founding Scientist NA
Dr. James A. Taylor Ph.D. Trials Consultant 1961
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR Trials Consultant 1948
Dr. Benjamin M. Segal Clinical Consultant NA
Dr. Frederick E. Reno Ph.D. Toxicology Consultant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…